Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Free Cash Flow (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Free Cash Flow for 4 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 52.61% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Dec 2025, down 27.85% year-over-year, with the annual reading at -$9.4 million for FY2025, 27.85% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$2.6 million at bioAffinity Technologies, down from -$2.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$376141.0 in Q2 2022, with the low at -$2.7 million in Q2 2025.
  • Average Free Cash Flow over 4 years is -$1.7 million, with a median of -$1.6 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 262.58% in 2023, then grew 29.1% in 2025.
  • Over 4 years, Free Cash Flow stood at -$1.3 million in 2022, then dropped by 23.24% to -$1.6 million in 2023, then dropped by 4.64% to -$1.7 million in 2024, then crashed by 52.61% to -$2.6 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.6 million, -$2.5 million, and -$2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.